Enrollment data

At this point, Covid, for better or for worse, is the driver of the stock price. If CYDY is first with a cure for the sickest of patients, it will have the playing field all to itself. That means profits to fund all the other indications. If others are approved first, especially if those companies are well known, we won't even make it to the evening news. If the market knows enrollment is moving at the right pace, the stock price will move accordingly. That's the reality. Second place is worth something. However, first place gets the biggest trophy and valuation. We need to finish first. It is ours to lose, as well as for the patients. Ask for the enrollment data. If enough people ask for it, we may get it. Then we'll know. And management will know everyone's watching. That usually improves the thinking mechanisms.

Most people who comment on this site believe the drug works. I also do. We need it to be the drug of choice. We need to be first. There should be no compromises of the care of patients. That is not related to the speed of enrollment.